| HCPCS | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Drug Class | Minor Drug Class | Oral (Y/N) | FDA Approval Year | FDA Discontinuation Year | CMS Effective Date | CMS Discontinuation Date | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| S0190 | Mifepristone | Korlym, Mifeprex | 200 mg | Hormonal Therapy | Antiprogestin | Cortisol Receptor Blocker | Yes | 2000 | Jan 1, 2001 | In Use | ||
| J9250 | Methotrexate | Trexall | 5 mg | Chemotherapy | Antimetabolite | Folic Acid Analog | Yes | 1953 | Jan 1, 1994 | Apr 17, 2024 | No Longer Used | |
| J8610 | Methotrexate | Trexall | 2.5 mg | Chemotherapy | Antimetabolite | Folic Acid Analog | Yes | 1953 | Jan 1, 1995 | In Use | ||
| NA | Ketoconazole | Apo-Ketoconazole | 200 mg | Hormonal Therapy | Androgen Receptor Inhibitor | Imidazole Derivative | Yes | 1981 | In Use | |||
| NA | isotretinoin | Absorica, Amnesteem, Claravis, Myorisan, Zenatane | many | Hormonal Therapy | Immunomodulator | Retinoic Acid Derivative | Yes | 1982 | In Use | |||
| NA | Afatinib | Gliotrif | 30 mg | Chemotherapy | Tyrosine Kinase Inhibitor | EGFR | Yes | 2013 | In Use | |||
| NA | Afatinib | Gliotrif | 40 mg | Chemotherapy | Tyrosine Kinase Inhibitor | EGFR | Yes | 2013 | In Use | |||
| NA | Palbociclib | Ibrance | 100 mg | Chemotherapy | Cyclin Dependent Kinase Inhibitor | CDK 4/6 | Yes | 2015 | In Use | |||
| NA | Ruxolitinib | Jakafi | 25 mg | Chemotherapy | Enzyme Inhibitor | JAK 1/2 | Yes | 2011 | In Use | |||
| NA | Ruxolitinib | Jakafi | 5 mg | Chemotherapy | Enzyme Inhibitor | JAK 1/2 | Yes | 2011 | In Use | |||
| NA | Pilocarpine Hydrochloride | Pilocarpine | 5mg, 10mg | Ancillary Therapy | Miscellaneous Agent | Cholinergic Agent | Yes | 2020 | In Use | |||
| Revumenib | Revuforj | 25mg, 110mg, 160mg | Chemotherapy | Enzyme Inhibitor | KMT2A | Yes | 2024 | In Use | ||||
| NA | Panobinostat | Farydak | 10 mg | Chemotherapy | Enzyme Inhibitor | HDAC | Yes | 2015 | In Use | |||
| Adagrasib | Krazati | 200mg | Immunotherapy | RAS Inhibitor | KrAS G12C | Yes | 2022 | In Use | ||||
| NA | Aprepitant | Emend | 125 mg | Ancillary Therapy | Antiemetic | Substance P/Neurokinin 1 | Yes | 2003 | In Use | |||
| NA | Cabozantinib | Cabometyx | 40 mg | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR | Yes | 2012 | In Use | |||
| NA | olaparib | Lynparza | 50 mg | Chemotherapy | Enzyme Inhibitor | PARP | Yes | 2014 | In Use | |||
| NA | oxymetholone | Anadrol-50 | 50 mg | Ancillary Therapy | Anabolic Steroid | Androgen | Yes | 1972 | In Use | |||
| NA | Ripretinib | Qinlock | 50mg | Chemotherapy | Tyrosine Kinase Inhibitor | KIT, PDGFRA | Yes | 2020 | In Use | |||
| NA | Binimetinib | Mektovi | 15mg | Chemotherapy | MEK Inhibitor | MEK 1/2 | Yes | 2018 | In Use | |||
| NA | Cabozantinib | Cometriq | 20 mg | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR | Yes | 2012 | In Use | |||
| NA | Afatinib | Gliotrif | 20 mg | Chemotherapy | Tyrosine Kinase Inhibitor | EGFR | Yes | 2013 | In Use | |||
| NA | venetoclax | Venclexta | 50 mg | Chemotherapy | Enzyme Inhibitor | BCL-2 | Yes | 2016 | In Use | |||
| C1086 | Temozolomide | Temodar | 5 mg | Chemotherapy | Alkylating Agent | Tetrazine | Yes | 1999 | Jan 1, 2010 | In Use | ||
| NA | Cabozantinib | Cabometyx | 20 mg | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR | Yes | 2012 | In Use |
The use of NA indicates that the HCPCS code was Not Available. NA may mean that a) the HCPCS code has
not yet been created (new drug), b) the drug is given as an oral drug or alternative route (only in
specific instances are HCPCS assigned to these medications), or c) the HCPCS could not be found or is
truly not available.
Home